GSK's Exdensur Approved in China for Severe Asthma, First Ultra-Long-Acting Biologic
Summary
GSK announced that China's NMPA has approved Exdensur (depemokimab) for severe asthma, marking it as the first and only ultra-long-acting biologic for the condition in the country.
Key Events
-
China NMPA Approval
China's National Medical Products Administration (NMPA) approved Exdensur (depemokimab) for severe asthma with an eosinophilic phenotype in patients aged 12 and older.
-
First Ultra-Long-Acting Biologic
Exdensur is the first and only ultra-long-acting biologic for severe asthma in China, offering a significant treatment option for over 2 million affected individuals.
-
Strong Clinical Efficacy
The approval is supported by SWIFT-1 and SWIFT-2 Phase III trials, which showed a significant reduction in asthma exacerbations and hospitalizations.
-
Global Market Expansion
This approval follows previous market authorizations for Exdensur in the US, Japan, EU, and UK, further expanding its global presence.
Analysis
This approval expands GSK's market reach for Exdensur into China, a significant market with over 2 million severe asthma patients. The drug's 'first and only' ultra-long-acting biologic status in China provides a competitive advantage, building on its prior approvals in the US, EU, UK, and Japan. This development strengthens GSK's respiratory portfolio and is expected to contribute positively to future revenue streams by addressing a substantial unmet medical need.
At the time of this filing, GSK was trading at $54.30 on NYSE in the Life Sciences sector, with a market capitalization of approximately $108.6B. The 52-week trading range was $32.38 to $61.70. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.